ING Group’s Clovis Oncology, Inc. CLVS Stock Holding History

ING Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-93,100	Closed	-$1.38M	–	794
2019 Q2	$1.38M	Buy	+93,100	New	+$1.68M	0.02%	325

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

ING Group's CLVS Position: Q3 2019 in Review

ING Group sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 93,100 shares — an estimated $1.38M sold.

ING Group first reported a position in CLVS in Q2 2019 and held it in 1 quarter. The position peaked at $1.38M in Q2 2019. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

ING Group reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
ING Group sold 93,100 Clovis Oncology, Inc. shares in Q3 2019, an estimated $1.38M.
ING Group first reported a position in Clovis Oncology, Inc. in Q2 2019 and held it in 1 quarter.
ING Group's Clovis Oncology, Inc. position peaked at $1.38M in Q2 2019.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on ING Group's 13F filing for Q3 2019, filed 8 Nov 2019.